BioDelivery Sciences International, Inc. (BDSI): Price and Financial Metrics


BioDelivery Sciences International, Inc. (BDSI): $5.59

-0.01 (-0.18%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add BDSI to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

BDSI Stock Price Chart Interactive Chart >

Price chart for BDSI

BDSI Price/Volume Stats

Current price $5.59 52-week high $5.62
Prev. close $5.59 52-week low $2.50
Day low $5.59 Volume 2,107,400
Day high $5.60 Avg. volume 3,340,554
50-day MA $4.56 Dividend yield N/A
200-day MA $3.81 Market Cap 577.05M

BioDelivery Sciences International, Inc. (BDSI) Company Bio


BioDelivery Sciences International, Inc. engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company was founded in 1997 and is based in Raleigh, North Carolina.


BDSI Latest News Stream


Event/Time News Detail
Loading, please wait...

BDSI Latest Social Stream


Loading social stream, please wait...

View Full BDSI Social Stream

Latest BDSI News From Around the Web

Below are the latest news stories about Biodelivery Sciences International Inc that investors may wish to consider to help them evaluate BDSI as an investment opportunity.

BioDelivery Sciences launches migraine therapy in U.S.

BioDelivery Sciences International (BDSI), a specialty pharmaceutical company focused on chronic conditions, announced the U.S. launch of its oral migraine therapy Elyxyb. Also known as celecoxib oral solution, Elyxyb is the first and only oral solution approved by the U.S. Food and Drug Administration (FDA) for the treatment of acute...

Seeking Alpha | February 24, 2022

BioDelivery Sciences International (BDSI) Just Flashed Golden Cross Signal: Do You Buy?

Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?

Yahoo | February 24, 2022

BioDelivery Sciences International Announces ELYXYB™ is Now Available in the U.S. for the Acute Treatment of Migraine

The First and Only FDA-Approved, Ready-to-Use Oral Solution for the Acute Treatment of Migraine with or without Aura in Adults Expands BDSI Portfolio and Establishes Growth Platform in Neurology RALEIGH, N.C., Feb. 24, 2022 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced the U.S. commercial launch and availability of ELYXYBTM (celecoxib

Yahoo | February 24, 2022

What to Expect From Precision BioSciences (DTIL) Q4 Earnings

On Precision BioSciences' (DTIL) Q4 earnings call, investor focus is likely to be on updates on the progress of the company's pipeline.

Yahoo | February 22, 2022

Biotech Stock Roundup: BDSI Surges on Merger Deal, SGEN Down on Outlook & More

Merger updates from BioDelivery (BDSI) and Seagen (SGEN) earnings results are among a few key highlights from the biotech sector during the past week.

Yahoo | February 16, 2022

Read More 'BDSI' Stories Here

BDSI Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year 53.99%
3-year 6.48%
5-year 143.04%
YTD N/A
2022 0.00%
2021 -26.19%
2020 -33.54%
2019 70.81%
2018 25.42%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7166 seconds.